222 related articles for article (PubMed ID: 28444427)
1. Population pharmacokinetic modelling of doxorubicin and doxorubicinol in children with cancer: is there a relationship with cardiac troponin profiles?
Kunarajah K; Hennig S; Norris RLG; Lobb M; Charles BG; Pinkerton R; Moore AS
Cancer Chemother Pharmacol; 2017 Jul; 80(1):15-25. PubMed ID: 28444427
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
[TBL] [Abstract][Full Text] [Related]
3. Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.
Völler S; Boos J; Krischke M; Würthwein G; Kontny NE; Boddy AV; Hempel G
Clin Pharmacokinet; 2015 Nov; 54(11):1139-49. PubMed ID: 25925711
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.
Krischke M; Hempel G; Völler S; André N; D'Incalci M; Bisogno G; Köpcke W; Borowski M; Herold R; Boddy AV; Boos J
Cancer Chemother Pharmacol; 2016 Dec; 78(6):1175-1184. PubMed ID: 27770238
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit.
Cusack BJ; Young SP; Driskell J; Olson RD
Cancer Chemother Pharmacol; 1993; 32(1):53-8. PubMed ID: 8462124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic modelling of acute N-terminal pro B-type natriuretic peptide after doxorubicin infusion in breast cancer.
Liang S; Brundage RC; Jacobson PA; Blaes A; Kirstein MN
Br J Clin Pharmacol; 2016 Sep; 82(3):773-83. PubMed ID: 27128712
[TBL] [Abstract][Full Text] [Related]
7. The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: insight to explain the cardiac safety of pixantrone in doxorubicin-treated patients.
Salvatorelli E; Menna P; Paz OG; Chello M; Covino E; Singer JW; Minotti G
J Pharmacol Exp Ther; 2013 Feb; 344(2):467-78. PubMed ID: 23192654
[TBL] [Abstract][Full Text] [Related]
8. Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver.
Booth CL; Brouwer KR; Brouwer KL
Cancer Res; 1998 Aug; 58(16):3641-8. PubMed ID: 9721873
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacokinetic profile of high-dose doxorubicin administered during a 6 h intravenous infusion in breast cancer patients].
Wihlm J; Limacher JM; Levêque D; Duclos B; Dufour P; Bergerat JP; Methlin G
Bull Cancer; 1997 Jun; 84(6):603-8. PubMed ID: 9295863
[TBL] [Abstract][Full Text] [Related]
10. Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?
Köseoğlu V; Berberoğlu S; Karademir S; Kismet E; Yurttutan N; Demirkaya E; Sungur M; Alehan D
Turk J Pediatr; 2005; 47(1):17-22. PubMed ID: 15884624
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic study of aldoxorubicin in patients with solid tumors.
Mita MM; Natale RB; Wolin EM; Laabs B; Dinh H; Wieland S; Levitt DJ; Mita AC
Invest New Drugs; 2015 Apr; 33(2):341-8. PubMed ID: 25388939
[TBL] [Abstract][Full Text] [Related]
12. Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood.
Liu Z; Martin J; Orme L; Seddon B; Desai J; Nicholls W; Thomson D; Porter D; McCowage G; Underhill C; Cranswick N; Michael M; Zacharin M; Herschtal A; Sivasuthan J; Thomas DM
Cancer Chemother Pharmacol; 2018 Nov; 82(5):887-898. PubMed ID: 30206658
[TBL] [Abstract][Full Text] [Related]
13. Toxicokinetics of the active doxorubicin metabolite, doxorubicinol, in sulphur-crested cockatoos (Cacatua galerita).
Gilbert CM; Filippich LJ; McGeary RP; Charles BG
Res Vet Sci; 2007 Aug; 83(1):123-9. PubMed ID: 17197005
[TBL] [Abstract][Full Text] [Related]
14. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients.
Robert J; Monnier A; Poutignat N; Hérait P
Cancer Chemother Pharmacol; 1991; 29(1):75-9. PubMed ID: 1742853
[TBL] [Abstract][Full Text] [Related]
17. A population pharmacokinetic model for doxorubicin and doxorubicinol in the presence of a novel MDR modulator, zosuquidar trihydrochloride (LY335979).
Callies S; de Alwis DP; Wright JG; Sandler A; Burgess M; Aarons L
Cancer Chemother Pharmacol; 2003 Feb; 51(2):107-18. PubMed ID: 12647011
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of doxorubicin and doxorubicinol in patients diagnosed with non-Hodgkin's lymphoma.
Pérez-Blanco JS; Santos-Buelga D; Fernández de Gatta MD; Hernández-Rivas JM; Martín A; García MJ
Br J Clin Pharmacol; 2016 Dec; 82(6):1517-1527. PubMed ID: 27447545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
